These data suggested that the T cells in this study can bind and be regulated by FGL2 in the tumor microenvironment through FcγRIIB and that T-αFGL2 treatment can disrupt this FcγRIIB-FGL2 interaction and boost the cytotoxic T cell response. The gene discussed is FCGR2B; the disease is neoplasm.